Target intelligence / Profile preview

GINS complex subunit 2 (GINS2)

Target
GINS2
Molecular classification
Other (core component of DNA replication initiation), DNA replication factor, Component of CDC45-MCM-GINS helicase complex
01

Overview

GINS complex subunit 2 (GINS2), also known as PSF2, is a critical component of the eukaryotic GINS complex, which consists of four subunits (Sld5, Psf1, Psf2/GINS2, and Psf3) and is essential for the initiation and elongation of DNA replication. GINS2 serves a scaffolding function in both DNA replication fork formation and progression by directly associating with the MCM2-7 complex and CDC45, forming the core of the CDC45-MCM-GINS (CMG) helicase that unwinds DNA at the replication fork. GINS2 is highly conserved and required for cell cycle progression, cell proliferation, and genomic stability[2][4][5]. Dysregulation or overexpression of GINS2 has been documented in numerous cancer types, where it promotes proliferation, invasion, epithelial-mesenchymal transition, migration, and is correlated with poor patient prognosis[1][3][7][9]. Knockdown of GINS2 induces G2/M cell cycle arrest and apoptosis via pathways such as p53/GADD45A and can attenuate tumorigenic potential in vitro and in vivo[3][7]. Because of its key regulatory checkpoints in the cell cycle and consistent overexpression in cancers, GINS2 is attracting attention as a potential molecular target and prognostic biomarker, though direct pharmacological targeting remains at an experimental or theoretical stage[1][6][7].

Other names
DNA replication complex GINS protein PSF2PSF2CGI-122DC5HSPC037Pfs2GINS2 (Psf2 homolog)
02

Biological functions

DNA replication initiationDNA replication fork progressionCell cycle regulationCell proliferationApoptosis
03

Disease associations

CancerSevere congenital neutropeniaOther (e.g., tumorigenesis in multiple solid cancers)
04

Safety considerations

Potential risk in targeting GINS2 due to its essential role in DNA replication and all dividing cells (may affect normal proliferative tissues)[2][5]
05

Biomarkers

Increased GINS2 expression as a prognostic biomarker in cancers (e.g., lung, breast, ovarian, sarcoma, cervical, pancreatic, colon)[1][3][7]

Beyond the preview

Go deeper on GINS complex subunit 2 (GINS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GINS complex subunit 2 (GINS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call